12/31/2010 | CVLM | Antigenics to exchange shares for $8.05 million of 5.25% convertibles
|
12/13/2010 | CVLM | Antigenics plans to buy back convertibles from majority holder Ingalls
|
4/22/2010 | CVLM | Antigenics issues shares for $2.29 million 5.25% convertibles, amends terms of 2006 convertibles
|
9/11/2009 | CV | Antigenics exchanges shares for $1.27 million 5.25% convertibles
|
8/4/2009 | PP | Market Commentary: Finders Resources plans equity sale; Antigenics to raise $10 million; Powertech secures loans
|
8/4/2009 | PP | New Issue: Antigenics negotiates $10 million private placement of stock, warrants
|
8/3/2009 | PP | New Issue: Antigenics completes $10 million private placement of stock, warrants
|
7/31/2009 | PP | New Issue: Antigenics to sell $10 million stock, warrants in private placement
|
7/31/2009 | PP | Market Commentary: Whitehaven to raise A$185 million; D'Aguilar plans internal placement; Armistice eyes PIPE
|
6/9/2009 | CV | Antigenics to swap shares for $2 million 5.25% convertibles due 2025
|
6/5/2009 | CV | Antigenics to exchange $1.5 million 5.25% convertibles for shares
|
6/4/2009 | CV | Antigenics agrees to issue stock for $12.4 million 5.25% convertibles
|
6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
2/19/2009 | CV | Antigenics buys back $11.8 million in convertibles
|
11/14/2008 | CV | Antigenics amends 2006 notes to allow repurchase of 5.25% convertibles
|
5/29/2008 | CVHY | Antigenics files $100 million shelf registration
|
4/9/2008 | PP | Market Commentary: Crosstex Energy seeks $100 million from units; Origen sells $46 million note with warrants
|
4/9/2008 | PP | New Issue: Antigenics plans $21 million private placement of stock
|
1/9/2008 | PP | New Issue: Antigenics announces $26.1 million private placement of stock
|
1/9/2008 | PP | Market Commentary: Transcendent One looks for broker in $3 million deal; Tassal pockets A$67.2 million
|
9/6/2007 | PP | Market Commentary: Antigenics looks into additional financing; BlueLine sure of $5 million Iridex stake
|
9/5/2007 | PP | New Issue: Antigenics announces $20.25 million placement of stock, preferreds
|
5/21/2007 | SS | Market Commentary: Alltel may see better bid; Cytyc climbs, Hologic hit; Pioneer up; Atlas Energy advances; WCI off
|
4/17/2007 | CV | Market Commentary: Antigenics eases after surge; BioMarin, Lawson gain in gray; Linear, Delta Petroleum launch deals
|
4/16/2007 | CV | Market Commentary: Antigenics climbs on drug data; Electronic Data flat as rumors continue; BioMarin, Lawson launch deals
|
2/21/2007 | CVSS | Antigenics ends 2006 with $40 million, reduces cash burn while growing pipeline
|
11/1/2006 | PP | Market Commentary: Qiao Xing Universal pockets $50 million; Electro-Optical seals $13.18 million PIPE
|
10/31/2006 | BT | Market Commentary: Alnylam, CytRx gain with Sirna; Antigenics gains; Viragen sinks; ZymoGenetics off ahead of results
|
10/31/2006 | PP | Market Commentary: Antigenics seals $25 million convertible notes offering; mergers may be boosting PIPE issuance
|
10/31/2006 | BTPP | New Issue: Antigenics arranges $25 million convertible notes offering
|
10/31/2006 | BT | Antigenics reports decrease in net loss as it reduces cash burn
|
8/8/2006 | BT | Market Commentary: Barrier loses 13%; Teva up more than 5%; Antigenics comes off highs; Amylin falls 7%
|
8/1/2006 | BT | Antigenics posts second-quarter net loss of $14.3 million, or $0.31 per share
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/10/2006 | BT | Antigenics announces expansion of license and supply agreements with GlaxoSmithKline Biologics
|
7/10/2006 | BT | Market Commentary: Connetics drops 33% on lowered forecast; Antigenics off 5%; Depomed off; Acadia gains
|
6/7/2006 | BT | Antigenics' in-depth analysis of Oncophage shows improvement in recurrence-free survival
|
6/7/2006 | BT | Market Commentary: Antigenics up 11% on data; Discovery Labs dives 19%; Incyte up; VaxGen slides
|
6/5/2006 | BT | Antigenics presents data showing Oncophage vaccine extends patients' lives
|
6/5/2006 | BT | Market Commentary: Genelabs stock skyrockets on Novartis collaboration; Antigenics stock falls on phase 3 Oncophage data
|
4/11/2006 | BT | Market Commentary: NitroMed, Antigenics strike new lows; NPS Pharma, Insmed gain; Medtronic deal boosts Biomet
|
3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
3/24/2006 | BT | Antigenics phase 3 study of kidney cancer patients fails to meet endpoints
|
12/6/2005 | BT | Antigenics cuts staff, narrows focus to save cash
|
11/21/2005 | BT | Antigenics initiates phase 1, 2 Oncophage trial for recurrent glioma
|
10/25/2005 | BT | Antigenics launches phase I study for newly formulated Aroplatin
|
10/19/2005 | BT | Stressgen's European patent upheld against challenge from Antigenics
|
10/18/2005 | BT | Antigenics starts phase I of AG-707 for genital herpes
|
8/25/2005 | BT | Market Commentary: Nastech rises in face of follow-on deal; Amylin up on takeover buzz; Antigenics convertible finds buyers
|
1/24/2005 | CV | Market Commentary: Rite Aid launches deal for Tuesday; Tower Auto bids bounce; Brocade news apt to boost bonds
|
1/21/2005 | CV | Market Commentary: Fortis/Assurant settles at 102.5; Celanese ends around par; Tower Automotive bonds in a freefall
|
1/20/2005 | CV | New Issue: Antigenics sells downsized $50 million convertible at 5.25%, up 20%
|
1/20/2005 | CV | Market Commentary: Celanese seen getting upsized; Fortis/Assurant issue bid well; Alexion, Antigenics trip out of chute
|
1/19/2005 | CV | Market Commentary: Alexion goes to 102; Antigenics sweetens terms; Charter exodus continues; auto, airline paper lower
|
1/18/2005 | CV | Antigenics $60 million convertible talked to yield 4.75%-5.25%, up 35%-40%
|
1/18/2005 | CV | Market Commentary: Antigenics, Alexion deals emerge; Charter slides on CEO's exit; Computer Network gains
|
11/27/2001 | CVHY | Antigenics files $100 million debt, preferred, stock, convertibles shelf
|